Phenylbutazone Injection 20% for Animal Medicine

• Customization: Available
• Varieties: Infectious Disease Prevention Medicine
• Component: Animal
• Pharmacodynamic Influential Factors: Animal Species
• Storage Method: Prevent High or LowTemperature
• Transport Package: 10ml 20ml 50ml 100ml 250ml 500ml
• Specification: 5% 10% 20%
• Trademark: HBNCP MOSSO SUNWAY
• Origin: China
• HS Code: 3004209020
• Production Capacity: 50000bottles/Day

Product Description

PHENYLBUTAZONE 20% INJECTION

For Horses Only 

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Each mL contains: Phenylbutazone ............................. 200 mg
Benzyl Alcohol Preservative .........10.45 mg
Sodium hydroxide to adjust pH to 9.5 to 10.0
Water For Injection ...............................q.s. 
DESCRIPTION: Phenylbutazone 20% Injection (phenylbutazone) is a synthetic, nonhormonal anti-inflammatory, antipyretic compound useful in the management of inflammatory conditions. The apparent analgesic effect is probably related mainly to the compound's anti-inflammatory properties.  Chemically, phenylbutazone is 4-butyl-1,2-diphenyl-3,5-pyrazolidinedione. It is a pyrazolon derivative entirely unrelated to the steroid hormones, and has the following structural formula:
INDICATIONS
For relief of inflammatory conditions associated with the musculoskeletal system in horses.

CONTRAINDICATIONS

Treated animals should not be slaughtered for food purposes. Parenteral injections should be made intravenously only; do not inject subcutaneously or intramuscularly. Use with caution in patients who have a history of drug allergy.

DOSAGE AND ADMINISTRATION

HORSES 
INTRAVENOUSLY: 1 to 2 g per 1,000 lbs of body weight (5 to 10 mL/1,000 lbs) daily. Injection should be given slowly and with care. Limit intravenous administration to a maximum of 5 successive days, which may be followed by oral phenylbutazone dosage forms.

PRECAUTIONS

Stop medication at the first sign of gastrointestinal upset, jaundice, or blood dyscrasia. Authenticated cases of agranulocytosis associated with the drug have occurred in man. To guard against this possibility, conduct routine blood counts at weekly intervals of two weeks thereafter. Any significant fall in th total white count, relative decrease in granulocytes, or black or tarry stools, should be regarded as a signal for immediate cessation of therapy and institution of appropriate counter measures. In the treatment of inflammatory conditions associated with infections, specific anti-infective therapy is required.

Store in cool and dark place.

Keep out of reach of children.

FOR VETRINARY USE ONLY

Manufacturer:
HEBEI NEW CENTURY PHARMACEUTICAL CO., LTD.
NO. 189 TAIHANG STREET, SHIJIAZHUANG, HEBEI, CHINA.